Testing effectiveness (Phase 2)Study completedNCT00302757
What this trial is testing
Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma
Who this might be right for
Non-Hodgkin Lymphoma
University Hospital Tuebingen 60